US5498537A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Serum-free production of packaged viral vector
Assignee: Cellco Inc
•
Filing: 1994-03-09
•
Granted: 1996-03-12
•
Expires: 2014-03-09
Abstract
Abstract The application concerns a method for the serum-free production of packaged and infectious vital vectors in an artificial capillary system cartridge. The invention further concerns transducing target cells with the vital vectors. The invention is particularly suitable for producing transduced target cells free of adherent serum proteins.
Inventors
- 👤 Herbert S. Bresler
- 👤 Richard A. Knazek
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 08:08
CPC Classifications
C; C12; C12N; C12N7/00; C12N2740/00; C12N2740/00011; C12N2740/10011; C12N2740/10051
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
77 words
A method for the production of packaged retroviral vectors, comprising: (a) inoculating PA-317 derived packaging cells which produce packaged and infectious retroviral vectors into an artificial capillary system (ACS) cartridge; (b) culturing said packaging cells in the presence of bovine serum-containing culture medium; (c) replacing said bovine serum-containing culture medium with bovine serum-free culture medium; and (d) culturing said packaging cells in the presence of said bovine serum-free culture medium to achieve packaged and infectious retroviral vectors.
Claim 2
Independent Claim
77 words
A method for the production of packaged retroviral vectors, comprising: (a) inoculating PA-317 derived packaging cells which produce packaged and infectious retroviral vectors into an artificial capillary system (ACS) cartridge; (b) culturing said packaging cells in the presence of bovine serum-containing culture medium; (c) replacing said bovine serum-containing culture medium with bovine serum-free culture medium; and (d) culturing said packaging cells in the presence of said bovine serum-free culture medium to achieve packaged and infectious retroviral vectors.
Claim 3
Dependent Claim
25 words
The method of claim 1 wherein said culturing occurs for a sufficient amount of time to produce high titers of packaged and infectious retroviral vectors.
Claim 4
Dependent Claim
14 words
The method of claim 1, wherein said retroviral vectors encode a therapeutically effective product.
Claim 5
Dependent Claim
12 words
The method of claim 1, wherein said recombinant retroviral vector is LNL-6.
Claim 6
Dependent Claim
21 words
The method of claim 1, further comprising: (e) collecting supernatant containing said packaged and infectious viral vectors from said ACS cartridge.
Claim 7
Dependent Claim
13 words
The method of claim 1, wherein said bovine serum-free culture medium is AIM-V.
References Cited (Backward Citations)
US3821087A
Cited
US4301250A
Cited
US4301249A
Cited
US4416986A
Cited
US4546083A
Cited
US4686098A
Cited
US4868116A
Cited
US4816401A
Cited
US4861719A
Cited
WO1990001870A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-03-12 | 1999-09-11 | 2000-03-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-03-12 | 2003-09-11 | 2004-03-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-03-12 | 2007-09-11 | 2008-03-12 | $7700.00 | Window Closed / Lapsed |